Magic mushroom compound tested for Long-Term depression relief
NCT ID NCT06605105
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is a long-term follow-up for people with major depressive disorder who already completed a previous trial with CYB003, a drug similar to psilocybin. It will test how safe and effective CYB003 is over time, with optional extra doses. About 468 participants will be monitored using a standard depression rating scale.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CYB003 (a deuterated psilocin analog, similar to the active compound in magic mushrooms)
What this could lead to
If successful, this could provide a new, long-term treatment option for people with major depressive disorder that may reduce symptoms with fewer doses than current antidepressants.
What could go wrong
This is an extension study, so participants already responded well in earlier trials. It is not a standalone test, and long-term side effects or loss of effectiveness are still possible. The drug is investigational and not yet approved.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MAJOR DEPRESSIVE DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Adams Clinical
Watertown, Massachusetts, 02472, United States
-
Adams Clinical Boston
Boston, Massachusetts, 02116, United States
-
Atlanta Center For Medical Research
Atlanta, Georgia, 30331, United States
-
Cedar Clinical Research
Draper, Utah, 84020, United States
-
CenExel iResearch
Savannah, Georgia, 31405, United States
-
Cenexel iResearcvh Atlanta, LLC
Atlanta, Georgia, 30030, United States
-
Clinical Neuroscience Solutions, Inc
Orlando, Florida, 32801, United States
-
Combined Research Orlando
Phoenix, Arizona, 85022, United States
-
InSite Clinical Research, LLC
DeSoto, Texas, 75115, United States
-
K2 Medical Research
Lady Lake, Florida, 32159, United States
-
Mountain View Clinical Research
Denver, Colorado, 80209, United States
-
Neurobehavioral Clinical Research
Canton, Ohio, 44720, United States
-
Open Mind Collective / UCSF Medical Center - Mount Zion
San Francisco, California, 94114, United States
-
Psychiatric Medicine Associates, LLC
Skokie, Illinois, 60076, United States
-
Research Centers of America
Hollywood, Florida, 33024, United States
-
Segal Trials Center for Psychedelic Research
Lauderhill, Florida, 33319, United States
-
Starlight Clinical Research
Evergreen, Colorado, 80439, United States
-
Sunstone Medical, PC
Rockville, Maryland, 20850, United States
-
Uptown Research Institute
Chicago, Illinois, 60640, United States